scholarly journals Introducing Hurdle_T as a Count Regression Model with High Potency in Solving Problems

Author(s):  
Ojekudo, Nathaniel Akpofure ◽  
Akpan, Nsikan Paul

Count data regression models exhibit different strengths and weaknesses in their bids to solving problems. The study considers six count models namely Poisson Regression Model (PRM), Negative Regression Model (NBRM), Zero Inflated Poisson (ZIP), Zero Inflated Negative Binomial (ZINB), Zero Truncated Poisson (ZTP) and Zero Truncated Negative Binomial (ZTNB) and an additional model called hurdle_T. These models are used to analyze two health data sets. The data on male breast cancer reveals that male breast cancer cuts across all age brackets or categories but it is more prevalent between the ages of 50 and 60. The PRM yields a better result than the NBRM in the case of cancer data as shown by the information criteria. The analysis of the second data, which is on doctor’s visit reveals that ZINB yields a better result than the other five models, followed by NBRM, then the ZTNB before their Poisson counterparts. The hurdle_T model shows the propensity of each coefficient as reflected by the positive count in the Tobit (Binary) model. The study also shows that at 65 years and above, gender has significant effect on doctor’s visit. In particular, females, more than males attract more doctors’ visit in the said age range. Government policies should provide more funds in the health sector to accommodate cancer cases in terms of the provision of awareness, studies/ research and infrastructural development. Males should be encouraged to visit clinics especially in their late forties and above for breast cancer related checkup. At age 65 and above, doctors visit to patients are frequent, especially to females. Policy of government in the health sector should accommodate a favourable adjustment in the budget to take care of doctors’ visit.

2011 ◽  
Vol 71 (08) ◽  
Author(s):  
H Eggemann ◽  
A Ignatov ◽  
R Stabenow ◽  
G von Minkwitz ◽  
FW Röhl ◽  
...  

Author(s):  
N Besic ◽  
B Cernivc ◽  
J De Greve ◽  
K Lokar ◽  
M Krajc ◽  
...  

1994 ◽  
Vol 31 (4) ◽  
pp. 759
Author(s):  
Kyung Joo Park ◽  
Chun Hwan Han ◽  
Jeong Geun Yi ◽  
Joo Hyuk Lee

1999 ◽  
Vol 61 (6) ◽  
pp. 760-762
Author(s):  
Hisatada HIROKAWA ◽  
Wataru RIKIHISA ◽  
Osamu YAMAMOTO ◽  
Yoshinori SUENAGA ◽  
Masakazu ASAHI

2016 ◽  
Vol 9 (2) ◽  
pp. 169-177 ◽  
Author(s):  
Laura Evangelista ◽  
Francesco Bertagna ◽  
Mattia Bertoli ◽  
Tigu Stela ◽  
Giorgio Saladini ◽  
...  

2020 ◽  
Vol 12 ◽  
pp. 175883592095835
Author(s):  
Wei-Ping Li ◽  
Hong-Fei Gao ◽  
Fei Ji ◽  
Teng Zhu ◽  
Min-Yi Cheng ◽  
...  

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no significant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jane Bayani ◽  
Coralie Poncet ◽  
Cheryl Crozier ◽  
Anouk Neven ◽  
Tammy Piper ◽  
...  

AbstractMale breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.


Sign in / Sign up

Export Citation Format

Share Document